Compare FATE & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FATE | DERM |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.6M | 135.3M |
| IPO Year | 2013 | 2021 |
| Metric | FATE | DERM |
|---|---|---|
| Price | $1.25 | $5.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $4.10 | ★ $12.67 |
| AVG Volume (30 Days) | ★ 1.2M | 187.9K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.88 | ★ 34.72 |
| EPS | N/A | ★ N/A |
| Revenue | $6,646,000.00 | ★ $61,858,000.00 |
| Revenue This Year | N/A | $39.72 |
| Revenue Next Year | N/A | $63.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 10.20 |
| 52 Week Low | $0.91 | $4.31 |
| 52 Week High | $1.94 | $9.56 |
| Indicator | FATE | DERM |
|---|---|---|
| Relative Strength Index (RSI) | 46.34 | 38.37 |
| Support Level | $0.95 | $4.31 |
| Resistance Level | $1.30 | $5.60 |
| Average True Range (ATR) | 0.08 | 0.26 |
| MACD | -0.01 | 0.10 |
| Stochastic Oscillator | 14.89 | 15.71 |
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.